TGE FT-ICR


Partenaires

CNRS
Logo Ecole Polytechnique Logo ESPCI
Logo UPS Logo UDL
Logo UPMC Logo Universite de Lille 1
Logo Rouen Logo INSA Rouen Normandie



Accueil du site > Production scientifique > Development of a matrix-assisted laser desorption/ionization–mass spectrometry screening test to evidence reversible and irreversible inhibitors of CDC25 phosphatases

Development of a matrix-assisted laser desorption/ionization–mass spectrometry screening test to evidence reversible and irreversible inhibitors of CDC25 phosphatases

Date de publication: 16 août 2012

E. Sibille, E. Bana, W. Chaouni, M. Diederich, D. Bagrel, P. Chaimbault
Anal. Biochem. 430 83-91 (2012). DOI

Travail réalisé sur le site de l’Université de Lorraine.

Abstract

"@@Insérer graphical abstract"

The cell division cycle 25 phosphatases (CDC25s) are key regulators of the physiological cell cycle progression. Their overexpression has been reported in a significant number of cancers, and their inhibition appears to be an interesting strategy for treatments. We propose here a rapid screening test allowing the detection of reversible and irreversible CDC25A and -C inhibitors. The test is based on the incubation of the candidate molecules with the human CDC25 proteins followed by an ultrafiltration step. The retentate is then directly analyzed by matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI–TOFMS) to detect reversible inhibitors or submitted to peptide mass fingerprint (PMF) analysis to reveal irreversible inhibitors covalently bound to the protein active site. After its validation, the protocol is applied to the detection of a novel candidate inhibitor of CDC25s named SV37. The screening procedure, as well as the preliminary biological results, demonstrates that this compound behaves as a reversible inhibitor